ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead ...

Low-cost preventative HIV medication may be ready as early as 2026, as British pharmaceutical company GSK strikes a deal allowing developing countries access to generic versions.

GSK Plc, seeking to snatch market share from Gilead Sciences Inc.’s best-selling HIV pill, said its long-acting shot works just as well and lets patients replace the daily medicine with an ...

LONDON – GlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to ...